Cargando…
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
BACKGROUND: Although a short course (7 days) of antibiotics has been demonstrated to be noninferior to a conventional course (14 days) in terms of mortality and infectious complications for patients with a Gram-negative bacterial bloodstream infection (GNB), it is unknown whether a shorter treatment...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125302/ https://www.ncbi.nlm.nih.gov/pubmed/35615299 http://dx.doi.org/10.1093/ofid/ofac140 |
_version_ | 1784711920186556416 |
---|---|
author | Howard-Anderson, Jessica Dai, Weixiao Yahav, Dafna Hamasaki, Toshimitsu Turjeman, Adi Koppel, Fidi Franceschini, Erica Hill, Carol Sund, Zoë Chambers, Henry F Fowler, Vance G Boucher, Helen W Evans, Scott R Paul, Mical Holland, Thomas L Doernberg, Sarah B |
author_facet | Howard-Anderson, Jessica Dai, Weixiao Yahav, Dafna Hamasaki, Toshimitsu Turjeman, Adi Koppel, Fidi Franceschini, Erica Hill, Carol Sund, Zoë Chambers, Henry F Fowler, Vance G Boucher, Helen W Evans, Scott R Paul, Mical Holland, Thomas L Doernberg, Sarah B |
author_sort | Howard-Anderson, Jessica |
collection | PubMed |
description | BACKGROUND: Although a short course (7 days) of antibiotics has been demonstrated to be noninferior to a conventional course (14 days) in terms of mortality and infectious complications for patients with a Gram-negative bacterial bloodstream infection (GNB), it is unknown whether a shorter treatment duration can provide a better overall clinical outcome. METHODS: We applied a bloodstream infection-specific desirability of outcome ranking (DOOR) analysis to the results of a previously completed, randomized controlled trial comparing short versus conventional course antibiotic therapy for hospitalized patients with uncomplicated GNB. We determined the probability that a randomly selected participant in the short course group would have a more desirable overall outcome than a participant in the conventional duration group. We performed (1) partial credit analyses allowing for calculated and variable weighting of DOOR ranks and (2) subgroup analyses to elucidate which patients may benefit the most from short durations of therapy. RESULTS: For the 604 patients included in the original study (306 short course, 298 conventional course), the probability of having a more desirable outcome with a short course of antibiotics compared with a conventional course was 51.1% (95% confidence interval, 46.7% to 55.4%), indicating no significant difference. Partial credit analyses indicated that the DOOR results were similar across different patient preferences. Prespecified subgroup analyses using DOOR did not reveal significant differences between short and conventional courses of therapy. CONCLUSIONS: Both short and conventional durations of antibiotic therapy provide comparable clinical outcomes when using DOOR to consider benefits and risks of treatment options for GNB. |
format | Online Article Text |
id | pubmed-9125302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91253022022-05-24 A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection Howard-Anderson, Jessica Dai, Weixiao Yahav, Dafna Hamasaki, Toshimitsu Turjeman, Adi Koppel, Fidi Franceschini, Erica Hill, Carol Sund, Zoë Chambers, Henry F Fowler, Vance G Boucher, Helen W Evans, Scott R Paul, Mical Holland, Thomas L Doernberg, Sarah B Open Forum Infect Dis Major Article BACKGROUND: Although a short course (7 days) of antibiotics has been demonstrated to be noninferior to a conventional course (14 days) in terms of mortality and infectious complications for patients with a Gram-negative bacterial bloodstream infection (GNB), it is unknown whether a shorter treatment duration can provide a better overall clinical outcome. METHODS: We applied a bloodstream infection-specific desirability of outcome ranking (DOOR) analysis to the results of a previously completed, randomized controlled trial comparing short versus conventional course antibiotic therapy for hospitalized patients with uncomplicated GNB. We determined the probability that a randomly selected participant in the short course group would have a more desirable overall outcome than a participant in the conventional duration group. We performed (1) partial credit analyses allowing for calculated and variable weighting of DOOR ranks and (2) subgroup analyses to elucidate which patients may benefit the most from short durations of therapy. RESULTS: For the 604 patients included in the original study (306 short course, 298 conventional course), the probability of having a more desirable outcome with a short course of antibiotics compared with a conventional course was 51.1% (95% confidence interval, 46.7% to 55.4%), indicating no significant difference. Partial credit analyses indicated that the DOOR results were similar across different patient preferences. Prespecified subgroup analyses using DOOR did not reveal significant differences between short and conventional courses of therapy. CONCLUSIONS: Both short and conventional durations of antibiotic therapy provide comparable clinical outcomes when using DOOR to consider benefits and risks of treatment options for GNB. Oxford University Press 2022-04-09 /pmc/articles/PMC9125302/ /pubmed/35615299 http://dx.doi.org/10.1093/ofid/ofac140 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Howard-Anderson, Jessica Dai, Weixiao Yahav, Dafna Hamasaki, Toshimitsu Turjeman, Adi Koppel, Fidi Franceschini, Erica Hill, Carol Sund, Zoë Chambers, Henry F Fowler, Vance G Boucher, Helen W Evans, Scott R Paul, Mical Holland, Thomas L Doernberg, Sarah B A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title | A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title_full | A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title_fullStr | A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title_full_unstemmed | A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title_short | A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection |
title_sort | desirability of outcome ranking analysis of a randomized clinical trial comparing seven versus fourteen days of antibiotics for uncomplicated gram-negative bloodstream infection |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125302/ https://www.ncbi.nlm.nih.gov/pubmed/35615299 http://dx.doi.org/10.1093/ofid/ofac140 |
work_keys_str_mv | AT howardandersonjessica adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT daiweixiao adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT yahavdafna adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hamasakitoshimitsu adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT turjemanadi adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT koppelfidi adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT franceschinierica adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hillcarol adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT sundzoe adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT chambershenryf adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT fowlervanceg adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT boucherhelenw adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT evansscottr adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT paulmical adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hollandthomasl adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT doernbergsarahb adesirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT howardandersonjessica desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT daiweixiao desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT yahavdafna desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hamasakitoshimitsu desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT turjemanadi desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT koppelfidi desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT franceschinierica desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hillcarol desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT sundzoe desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT chambershenryf desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT fowlervanceg desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT boucherhelenw desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT evansscottr desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT paulmical desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT hollandthomasl desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection AT doernbergsarahb desirabilityofoutcomerankinganalysisofarandomizedclinicaltrialcomparingsevenversusfourteendaysofantibioticsforuncomplicatedgramnegativebloodstreaminfection |